Trastuzumab Deruxtecan Rechallenge in HER2-Positive Metastatic Breast Cancer: EN-SEMBLE

The Breast·July 22Open Access

Obstetrics & Gynecology HER2-Positive Metastatic Breast Cancer Antibody-Drug Conjugate Enhertu Trastuzumab Deruxtecan

Summary

What was studied

The EN-SEMBLE study evaluated trastuzumab deruxtecan (T-DXd) rechallenge in patients with HER2-positive metastatic breast cancer who had previously received and progressed on T-DXd.

Trastuzumab Deruxtecan Rechallenge in HER2-Positive Metastatic Breast Cancer: EN-SEMBLE

Summary

What was studied

Related Questions

Trastuzumab Deruxtecan Rechallenge in HER2-Positive Metastatic Breast Cancer: EN-SEMBLE

Summary

What was studied

Related Questions